Protective effect of N-glycan bisecting GlcNAc residues on -amyloid production in Alzheimer's disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Alteration of glycoprotein glycans often changes various properties of the target glycoprotein and contributes to a wide variety of diseases. Here, we focused on the N-glycans of amyloid precursor protein whose cleaved fragment, beta-amyloid, is thought to cause much of the pathology of Alzheimer's disease (AD). We previously determined the N-glycan structures of normal and mutant amyloid precursor proteins (the Swedish type and the London type). In comparison with normal amyloid precursor protein, mutant amyloid precursor proteins had higher contents of bisecting GlcNAc residues. Because N-acetylglucosaminyltransferase III (GnT-III) is the glycosyltransferase responsible for synthesizing a bisecting GlcNAc residue, the current report measured GnT-III mRNA expression levels in the brains of AD patients. Interestingly, GnT-III mRNA expression was increased in AD brains. Furthermore, beta-amyloid treatment increased GnT-III mRNA expression in Neuro2a mouse neuroblastoma cells. We then examined the influence of bisecting GlcNAc on the production of beta-amyloid. Both beta-amyloid 40 and beta-amyloid 42 were significantly decreased in GnT-III-transfected cells. When secretase activities were analyzed in GnT-III transfectant cells, alpha-secretase activity was increased. Taken together, these results suggest that upregulation of GnT-III in AD brains may represent an adaptive response to protect them from additional beta-amyloid production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 1×
“The Swedish type mutation (Lys595/Met596 to Asn/Leu) increases Aβ42 secretion by 6to 7-fold (Citron et al. 1992) and the London type mutation (Val642 to Phe) doubles the ratio of secreted Aβ42 to Aβ40 (Suzuki et al.”
BackgroundSuzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471
Schachter, H. (1986) · Biochemistry and Cell Biology · doi:10.1139/o86-026 · Cited by 526
Wang, X., Inoue, S., Gu, J., Miyoshi, E., Noda, K., Li, W., Mizuno-Horikawa, Y., Nakano, M., Asahi, M., Takahashi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507375102 · Cited by 476 · cited 1×
“Glycoproteins glycans affect protein stability, conformation, cellular localization, and trafficking (Wang et al. 2005; Ohtsubo and Marth 2006).”
Self-citationBenjannet, S., Elagoz, A., Wickham, L., Mamarbachi, M., Munzer, J. S., Basak, A., Lazure, C., Cromlish, J. A., Sisodia, S., Checler, F., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009899200 · Cited by 301
Aberrant Glycosylation of E-cadherin Enhances Cell-Cell Binding to Suppress Metastasis
Yoshimura, M., Ihara, Y., Matsuzawa, Y., & Taniguchi, N. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13811 · Cited by 209 · cited 1×
“For example, in cells that overexpress GnT-III, cell surface turnover of E-cadherin is delayed (Yoshimura et al. 1996).”
BackgroundSelf-citationDifferential glycosylation regulates processing of lipoprotein receptors by γ-secretase
May, P., Bock, H. H., Nimpf, J., & Herz, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305858200 · Cited by 142 · cited 1×
“For example, organ-specific differential glycosylation of low-density lipoprotein receptor-related protein 1 (LRP1) alters its proteolytic cleavage by γ-secretase (May et al. 2003).”
BackgroundSialylation enhances the secretion of neurotoxic amyloid‐β peptides
Nakagawa, K., Kitazume, S., Oka, R., Maruyama, K., Saido, T. C., Sato, Y., Endo, T., & Hashimoto, Y. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03595.x · Cited by 83
Self-citation
Cited by
The role of protein glycosylation in Alzheimer disease
Schedin‐Weiss, S., Winblad, B., & Tjernberg, L. O. (2014) · The FEBS Journal · doi:10.1111/febs.12590 · Cited by 317
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease
Kizuka, Y., Kitazume, S., Fujinawa, R., Saito, T., Iwata, N., Saido, T. C., Nakano, M., Yamaguchi, Y., Hashimoto, Y., Staufenbiel, M., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404438 · Cited by 185
Self-citationBACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease
Barão, S., Moechars, D., Lichtenthaler, S. F., & De Strooper, B. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.01.003 · Cited by 158
Implications of Glycosylation in Alzheimer’s Disease
Haukedal, H., & Freude, K. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.625348 · Cited by 114
CSF N-glycoproteomics for early diagnosis in Alzheimer's disease
Palmigiano, A., Barone, R., Sturiale, L., Sanfilippo, C., Bua, R. O., Romeo, D. A., Messina, A., Capuana, M. L., Maci, T., Le Pira, F., et al. (2016) · Journal of Proteomics · doi:10.1016/j.jprot.2015.10.006 · Cited by 107
Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions
Kizuka, Y., Nakano, M., Kitazume, S., Saito, T., Saido, T. C., & Taniguchi, N. (2016) · Biochemical Journal · doi:10.1042/bj20150607 · Cited by 85
Self-citationRole and therapeutic implications of protein glycosylation in neuroinflammation
Rebelo, A. L., Chevalier, M. T., Russo, L., & Pandit, A. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.01.004 · Cited by 50
The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases
Zhang, L., Zhang, W., & Tian, X. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2021.1924707 · Cited by 54
Metadata
- Authors
- Akasaka-Manya, K., Manya, H., Sakurai, Y., Wojczyk, B. S., Kozutsumi, Y., Saito, Y., Taniguchi, N., Murayama, S., Spitalnik, S. L., & Endo, T.
- Venue
- Glycobiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-09-23
- Volume
- 20
- Issue
- 1
- Pages
- 99-106
- ISSN
- 0959-6658 (ISSN-L)
- 1460-2423
- OpenAlex
- W2104371012
- Cited by
- 102
- References
- 8
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.